Allergology international : official journal of the Japanese Society of Allergology · 2026
Dual clinical remission in patients treated with biologics for severe asthma and eosinophilic chronic rhinosinusitis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Takahashi Naoko, Kojima Ayako, Numata Takanori, Okuda Keitaro, Miyagawa Hanae, Yoshida Masahiro, Ito Saburo, Minagawa Shunsuke, Ishikawa Takeo, Hara Hiromichi, Otori Nobuyoshi, Araya Jun
Аннотация
BACKGROUND: Severe asthma (SA) and eosinophilic chronic rhinosinusitis (ECRS) are characterized by type 2 inflammation, and several biological agents are available. Data on dual clinical remission (CR) in patients with both conditions are limited.
METHODS: To elucidate the proportion of patients achieving dual CR and its predictors among patients with both SA and ECRS, 67 patients (24 males) with both conditions who received biologics for ≥12 months from July 2009 to February 2025 at Jikei University Hospital were retrospectively evaluated.
RESULTS: The mean age at biologics initiation was 53.9 years. After switching biologics, the final biologics were omalizumab (1 patient), mepolizumab (13), benralizumab (23), dupilumab (25), tezepelumab (3), and a combination (2). CR for SA occurred in 37 % of patients according to four criteria, i.e., no exacerbation, no systemic corticosteroids (SCS), no symptoms, and stabilization of pulmonary function. For ECRS, 54 patients underwent surgery (mean: 1.6 times). Of the 47 patients who received biologics following surgery, the median time from surgery to biologics initiation was 44 months. CR for ECRS occurred in 60 % of patients according to four criteria, i.e., no symptoms, no SCS, no endoscopic findings, and no need for additional surgery. Dual CR occurred in 25 % of patients, and the predictors included age ≥65 years (P < 0.0001) and the presence of nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) as a comorbidity (P = 0.0003).
CONCLUSIONS: Dual CR with biologics treatment may be achieved in elderly patients and in those with N-ERD among patients with both SA and ECRS.
METHODS: To elucidate the proportion of patients achieving dual CR and its predictors among patients with both SA and ECRS, 67 patients (24 males) with both conditions who received biologics for ≥12 months from July 2009 to February 2025 at Jikei University Hospital were retrospectively evaluated.
RESULTS: The mean age at biologics initiation was 53.9 years. After switching biologics, the final biologics were omalizumab (1 patient), mepolizumab (13), benralizumab (23), dupilumab (25), tezepelumab (3), and a combination (2). CR for SA occurred in 37 % of patients according to four criteria, i.e., no exacerbation, no systemic corticosteroids (SCS), no symptoms, and stabilization of pulmonary function. For ECRS, 54 patients underwent surgery (mean: 1.6 times). Of the 47 patients who received biologics following surgery, the median time from surgery to biologics initiation was 44 months. CR for ECRS occurred in 60 % of patients according to four criteria, i.e., no symptoms, no SCS, no endoscopic findings, and no need for additional surgery. Dual CR occurred in 25 % of patients, and the predictors included age ≥65 years (P < 0.0001) and the presence of nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) as a comorbidity (P = 0.0003).
CONCLUSIONS: Dual CR with biologics treatment may be achieved in elderly patients and in those with N-ERD among patients with both SA and ECRS.